Login to Your Account

Clinic Roundup

Tuesday, June 14, 2011
VIA Pharmaceuticals Inc., of San Francisco, announced dosing of the first healthy volunteers in a Phase I trial of VIA-3196, the company's orally administered, liver-directed thyroid hormone beta receptor agonist for the treatment of high LDL cholesterol and other dyslipidemias including high triglycerides and elevated Lp (a).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription